Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,166 across all filing types
Latest filing 2026-05-25 Regulatory Filings
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Intimation about participating in the Analyst/Institutional Investors Meet.
Regulatory Filings Classification · 80% confidence The document is a stock exchange disclosure under SEBI Listing Regulations (Regulation 30) announcing Lupin’s participation in upcoming Analyst/Institutional Investor Meets. It does not contain financial data or a presentation itself, nor does it announce voting results or board changes. This is a general regulatory announcement, classifying as Regulatory Filings (RNS).
2026-05-25 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 14% confidence The document is a statutory disclosure under SEBI Listing Regulations (Regulation 30) informing the stock exchanges of upcoming analyst/institutional investor meet events. It does not contain financial statements, earnings data, or a report itself, nor is it announcing publication of a report. It is a general regulatory announcement for compliance purposes. Therefore, it falls under the fallback category Regulatory Filings (RNS).
2026-05-25 English
Lupin Receives China Approval for Oseltamivir Phosphate Oral Suspension.
Regulatory Filings Classification · 75% confidence The document is a press release filed under SEBI LODR Regulation 30 to Indian stock exchanges announcing a product approval in China. It is a general regulatory disclosure rather than an annual or interim financial report, earnings release, management discussion, or other specific filing category. It does not contain financial statements or detailed investor presentation content. Therefore, it falls under the general Regulatory Filings category (RNS).
2026-05-22 English
Press Release
Regulatory Filings Classification · 10% confidence The document is a press release submitted under SEBI Listing Regulations 2015 (Regulation 30) to stock exchanges, announcing China regulatory approval of a product. It contains no financial results, no meeting materials, no share transactions, and no actual report or financial statements. This falls under general regulatory disclosure announcements, which are classified as Regulatory Filings (RNS).
2026-05-22 English
Annual Secretarial Compliance Report of Lupin Limited for the Financial year ended March 31, 2026.
Regulatory Filings Classification · 88% confidence The document is a Secretarial Compliance Report issued under SEBI Listing Regulations (“annual secretarial compliance report for the year ended March 31, 2026”) and is submitted by the company to the stock exchanges as required by Regulation 24A. It does not contain financial statements or substantive analysis typical of an Annual Report or Interim Report, nor is it an earnings release, governance code, or proxy solicitation. It is primarily a compliance certification by company secretaries, which per the certification rule should be classified as a general regulatory filing. Therefore, it falls under Regulatory Filings (RNS).
2026-05-20 English
Lupin Makes its Debut in Dow Jones Best-in-Class Indices 2026.
Regulatory Filings Classification · 88% confidence The document is a press release filed under SEBI Regulation 30 to stock exchanges announcing Lupin’s inclusion in the Dow Jones Best-in-Class ESG indices. It does not contain financial statements, earnings data, or substantive ESG report content; rather, it is a regulatory-required disclosure/press release. This falls into the miscellaneous regulatory announcement category.
2026-05-19 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.